# Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

> **NCT02683941** · PHASE3 · TERMINATED · sponsor: **Ipsen** · enrollment: 77 (actual)

## Conditions studied

- Neuroendocrine Tumors in Lung

## Interventions

- **DRUG:** Lanreotide (Autogel formulation)
- **DRUG:** Placebo
- **DRUG:** Best Supportive Care

## Key facts

- **NCT ID:** NCT02683941
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-06
- **Primary completion:** 2020-02-28
- **Final completion:** 2020-02-28
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** National Comprehensive Cancer Network \& European Neuroendocrine Tumor Society guidelines (2015/2016) led to prescription of somatostatin analogues (SSAs) in this setting, thereby limiting recruitment.
- **Last updated:** 2022-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02683941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02683941, "Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT02683941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*